Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Richard J. Fitzgerald, Laura Dickinson, Laura Else, Thomas Fletcher, Colin Hale, Alieu Amara, Lauren Walker, Sujan Dilly Penchala, Rebecca Lyon, Victoria Shaw, William Greenhalf, Katie Bullock, Lara Lavelle-Langham, Helen Reynolds, Wendy Painter, Wayne Holman, Sean Ewings, Gareth Griffiths, Saye Khoo
Abstract
ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and nasal NHC were significantly correlated with plasma (P < .0001). Clinical Trials Registration. NCT04746183.
Topics & Concepts
ProdrugSalivaPharmacokineticsNucleosideMedicineNucleoside analogueClinical trialTransmission (telecommunications)Coronavirus disease 2019 (COVID-19)CoronavirusRespiratory systemPharmacologyGastroenterologyInternal medicineVirologyChemistryBiochemistryDiseaseInfectious disease (medical specialty)EngineeringElectrical engineeringSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingRespiratory viral infections research